The blood resistin level in patients with DM2, depending on the duration of the disease

• Authors: Alina Urbanovych
• Languages of publication: EN

Abstracts

EN

Resistin is still a little known hormone of the adipose tissue. The potential role of resistin in the development of DM2 has been currently investigated. The aim of our study was to detect the resistin blood level in patients with DM2, depending on the duration of the disease. In so doing, a determination of resistin and insulin blood level was conducted in 305 patients with DM2, and in a control group of 32 persons. Before testing, the patients were placed into four groups, depending on the duration of type 2 diabetes. Our results indicate that the resistin level was significantly lower in the control group of patients, in comparison with the DM2 patients groups. Moreover, a significantly lower resistin level was found in group I (firstly diagnosed DM2), in comparison with the groups of patients with a different duration of DM2. No correlation between resistin level and BMI, and between resistin and insulin blood level was found. However, a tendency towards increase of resistin blood level is noticeably evident in co-relation with increment of DM2 duration. In addition, the resistin level was considerably lower in patients with no DM2, when compared with patients with diagnosed DM2. Yet, there was no significant difference in the resistin blood level depending on the sex of the patients at the same duration of DM2

Keywords

EN

resistin; diabetes mellitus type 2 (DM2); insulin

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2015
• Volume: 28
• Issue: 2
• Pages: 111-114

Dates

published

1 - 6 - 2015

online

16 - 7 - 2015

accepted

24 - 3 - 2015

received

27 - 2 - 2015

Contributors

author

Alina Urbanovych

• Department of Endocrinology, Lviv National Medical University, Pekarska 69, 79010, Lviv, Ukraine

References

• 1. Bauer S. et al.: Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J. Diabetes Complications, 2011, 25:377-381.[WoS][Crossref]
• 2. Cao H., Hegele R.: Single nucleotide polymorphisms of the resistin (RSTN) gene. J. Hum Genet., 2001; 46: 553-555.
• 3. Ebtesam A Al-Suhaimi, Adeeb Shehzad.: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. European Journal of Medical Research, 2013, 18:12.[WoS][Crossref]
• 4. Fujinami A. et al.: Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta, 2004; 339 (1-2): 57-63.
• 5. Hasegawa G., et al.: Plasma concentrations of resistin in type 2 diabetic patients. Diabetes, 2003; 52 (1): 82-83.
• 6. Janke J. et al.: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res., 2002; 10: 1-5.[Crossref]
• 7. Jinhua Yin et al.: Measurement of Salivary Resistin Level in Patients with Type 2 Diabetes. International Journal of Endocrinology, 2012; 2012: Article ID 359724, 5 p.
• 8. Lauders M et al.: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res., 2010 Apr;42(4):268-73
• 9. Lee J.H. et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans, and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab., 2003; 88: 4848-4856.
• 10. McTernan C.L. et al.: Resistin, central obesity, and type 2 diabetes. Lancet, 2002; 36: 46-7.
• 11. Meier U., Gressner A.M.: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem., 2004; 50: 1511-1525.
• 12. Nagaev I, Smith U.: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun., 2001; 285: 561-564.
• 13. Rajala M. et al.: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 2004; 53 (7): 1671-1679.[Crossref]
• 14. Rangwala S. et al.: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 2004; 53: 1937-1941.[Crossref]
• 15. Shuldier A., Yang R., Gong D.W.: Resistin, obesity and insulin resistance. N Engl J Med., 2001; 345: 1345-1346.
• 16. Steppan C.M. et al.: The hormone resistin links obesity to diabetes. Nature, 2001; 409: 307-12.
• 17. Tokuyama Y. et al.: Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism, 2007; 56 (5): 693-698.[Crossref][WoS]
• 18. Vozarova De Courten B. et al.: High serum resistin is associated with an increase in adiposity but not worsening of insulin resistance in Pima Indian. Diabetes, 2004; 53 (9): 1279-1284.[Crossref]

Identifiers

DOI

10.1515/cipms-2015-0055